Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film
Cybin Corp. (“Cybin” or the “Company”), Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, is pleased to announce that it has entered into a feasibility agreement with IntelGenx Corp. (OTCQB:IGXT; TSX-V:IGX) (“IntelGenx”) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals.
“We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” said Cybin’s Chief Medical Officer, Dr. Jukka Karjalainen. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high. In addition, the dose of psilocybin administered by an orally-dissolving film is expected to be a fraction of what is required in oral capsules. Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.”
“Cybin's intention with an orally-dissolving psilocybin film is to bypass the digestive system, which will provide faster-acting relief for individuals with anxiety disorders who require more immediate symptom relief,” added Cybin’s Chief Executive Officer, Paul Glavine.
Dr. Horst G. Zerbe, CEO of IntelGenx, commented, “This partnership exemplifies both the versatility and clinical advantages of our VersaFilm® technology platform. In addition to offering patients a convenient method of administration, our technology offers superior drug bioavailability, which decreases both the amount of active pharmaceutical ingredient required per dose, as well as time to onset of action, which are paramount when treating distressing conditions such as anxiety. We are looking forward to working with Cybin to realize these potential benefits for patients struggling with mental health disorders.”
About Cybin
Cybin is a mushroom life sciences company advancing psychedelic and nutraceutical-based products. The Company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the Company is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical delivery films.
IntelGenx’s superior film technologies, including VersaFilm® and VetaFilm™, as well as its transdermal development and manufacturing capabilities, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot-and commercial-scale production. For more information, visit www.intelgenx.com.
Forward Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the ability to receive regulatory approvals, the bioavailability of the film, the potential safety and efficacy of psilocybin administered in an orally-dissolving film, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this press release are made as of the date of this press release. The Company does not undertake an obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005296/en/
Contact information
Sara Brittany Somerset
Email: sarabrittany@cybin.com
www.cybin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GeologicAI Announces Acquisition of Lumo Analytics to Complete Its Integrated Sensor Suite Across Critical Minerals and Rare Earth Elements17.12.2025 18:53:00 EET | Press release
GeologicAI, the global leader in High-Resolution Decision Engineering for the critical minerals sector, today announced its acquisition of Lumo Analytics, a provider of the most compact and efficient Laser-Induced Breakdown Spectroscopy (LIBS) scanner in the market. LIBS is a rapid, non-destructive technique that uses a high-energy laser pulse to vaporize a tiny spot on a rock, creating a short-lived plasma which emits light unique to the elements present when it cools. This spectral “fingerprint” provides immediate chemical information about the material. For the mining sector, this means faster geochemical insights directly at the source, enabling more efficient exploration and resource evaluation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217715846/en/ The transaction firmly cements GeologicAI’s position as the only truly comprehensive and integrated source of sensor data for the critical minerals industry. Buildi
Incyte Announces European Commission Approval of Minjuvi ® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma17.12.2025 18:20:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy. "The EC approval of Minjuvi addresses a critical need, bringing a new, first-of-its-kind, chemotherapy-free option to patients in Europe with relapsed or refractory FL,” said Bill Meury, President and Chief Executive Officer, Incyte. “Historically, FL patients have had limited treatment options in the second-line setting, and we are proud to drive this important advancement for the lymphoma community as we seek to deliver innovative medicines for patients with cancer.” The EC decision follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in November 2025. This marks the second indication for Minjuvi, which was previo
Rigaku Launches ONYX 3200, a Metrology Instrument for Semiconductor Manufacturing17.12.2025 17:00:00 EET | Press release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) announced the launch of the ONYX 3200, a new semiconductor metrology system to measure film thickness, composition and bump* structures for wafer-level processes. The system is engineered to help manufacturers stabilize quality and increase yield in the metal-wiring formation (back-end-of-line (BEOL)) and packaging processes of semiconductor chips. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216597402/en/ ONYX 3200 Due to accelerating demands for AI, high-performance computing, data centers, mobile devices, and other devices, chip wiring and interconnect structures have grown increasingly delicate and complex. As a result, the ability to accurately and non-destructively measure metal layers thinner than a human hair and bump
Taylor Wessing Diversifies Its International Strategy17.12.2025 16:05:00 EET | Press release
International law firm Taylor Wessing is set to diversify its strategy within its international alliance, in order to push international growth and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217415857/en/ Dr. Oliver Bertram, Global Co-Chair at Taylor Wessing The English part of the partnership is seeking a merger with US law firm Winston & Strawn and would – depending on a corresponding partner decision, which is still pending – leave the Taylor Wessing alliance at the end of April 2026. Both parties wish to continue their successful joint international client work unchanged. Therefore, collaboration between Taylor Wessing and future Anglo-American firm Winston Taylor will continue seamlessly based on a cooperation agreement, ensuring that clients will not experience any change in their collaboration with Taylor Wessing. With the firm’s new open strategy, Taylor Wessing equally meets the strategic requirem
ISACA to Lead Global Credentialing for CMMC Cybersecurity Framework as International Cyber Readiness Standards Rise17.12.2025 16:00:00 EET | Press release
As cyber threats escalate and governments raise expectations around operational resilience, ISACA has been appointed to lead the global credentialing programme for the U.S. DoW’s Cybersecurity Maturity Model Certification (CMMC) program. The appointment positions ISACA – the international association for cybersecurity, audit and digital trust – as the exclusive CMMC Assessor and Instructor Certification Organization (CAICO), responsible for training, examining and certifying professionals, assessors, and instructors across the CMMC ecosystem. Originally developed by the U.S. DoW to protect sensitive unclassified information within its global supply chain, CMMC is increasingly relevant to European defence, aerospace, engineering and high-technology companies participating in transatlantic programmes. As the framework is phased into U.S. procurement from 2025 to 2028, many European organisations that handle Controlled Unclassified Information (CUI) or Federal Contract Information (FCI),
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom